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Abstract
Large-scale serological testing in the population is essential to determine the true extent of
the current SARS-CoV-2 pandemic. Serological tests measure antibody responses against
pathogens and use predefined cutoff levels that dichotomize the quantitative test measures
into sero-positives and negatives and use this as a proxy for past infection. With the imperfect
assays that are currently available to test for past SARS-CoV-2 infection, the fraction of sero-
positive individuals in serosurveys is a biased estimator of the cumulative incidence and is
usually corrected to account for the sensitivity and specificity. Here we use an inference
method—referred to as mixture-model approach—for the estimation of the cumulative inci-
dence that does not require to define cutoffs by integrating the quantitative test measures
directly into the statistical inference procedure. We confirm that the mixture model outper-
forms the methods based on cutoffs, leading to less bias and error in estimates of the cumula-
tive incidence. We illustrate how the mixture model can be used to optimize the design of
serosurveys with imperfect serological tests. We also provide guidance on the number of con-
trol and case sera that are required to quantify the test’s ambiguity sufficiently to enable the
reliable estimation of the cumulative incidence. Lastly, we show how this approach can be
used to estimate the cumulative incidence of classes of infections with an unknown distribu-
tion of quantitative test measures. This is a very promising application of the mixture-model
approach that could identify the elusive fraction of asymptomatic SARS-CoV-2 infections. An
R-package implementing the inference methods used in this paper is provided. Our study
advocates using serological tests without cutoffs, especially if they are used to determine
parameters characterizing populations rather than individuals. This approach circumvents
some of the shortcomings of cutoff-based methods at exactly the low cumulative incidence
levels and test accuracies that we are currently facing in SARS-CoV-2 serosurveys.
Author summary
As other pathogens, SARS-CoV-2 elicits antibody responses in infected people that can
be detected in their blood serum as early as a week after the infection until long after
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recovery. The presence of SARS-CoV-2 specific antibodies can therefore be used as a
marker of past infection, and the prevalence of seropositive people, i.e. people with spe-
cific antibodies, is a key measure to determine the extent of the SARS-CoV-2 pandemic.
The serological tests, however, are usually not perfect, yielding false positive and false
negative results. Here we exploit an approach that refrains from classifying people as sero-
positive or negative, but rather compares the antibody level of an individual to that of con-
firmed cases and controls. This approach leads to more reliable estimates of cumulative
incidence, especially for the low prevalence and low test accuracies that we face during
the current SARS-CoV-2 pandemic. We also show how this approach can be extended to
infer the presence of specific types of cases that have not been used for validating the test,
such as people that underwent a mild or asymptomatic infection.
This is a PLOS Computational BiologyMethods paper.
Introduction
Past SARS-CoV-2 infection can be detected with serological tests, which classify individuals as
sero-positive when their antibody level exceeds a predefined cutoff-value. Such serological
tests are imperfect; currently available tests have high specificity but relatively low sensitivity
[1–7]. Thus, they can give rise to false positive and false negative results. Such incorrect test
outcomes are particularly problematic when the serological tests are used to determine the
immune status of individuals. To estimate the cumulative incidence in a population, however,
the accurate determination of the serological status of each individual is not required, as it is
possible to correct for the sensitivity and specificity of the serological test.
It is well known that the proportion of positive tests in a serosurvey is a biased estimator of
cumulative incidence. Tests with a high specificity and low sensitivity, for example, underesti-
mate the cumulative incidence because the low sensitivity leads to a high frequency of false
negatives. Post-hoc corrections of the binomial estimator have been developed and refined
over the past decades [8–10], and have been applied to SARS-CoV-2 serosurveys [11]. More
specifically, Rogan and Gladen describe a post-hoc correction that essentially subtracts the
expected number of false positives and adds the expected number of false negatives to the
binomial estimator [8]. However, this Rogan-Gladen estimator works well only for high
cumulative incidence and relatively high test specificity [8]. Additionally, the uncertainty in
the sensitivity and specificity is not taken into account by the Rogan-Gladen estimator of the
cumulative incidence.
An estimator that considers the uncertainty in the sensitivity and specificity is, in this study,
referred to as the Bayesian framework. In this framework, the uncertainty in the sensitivity and
specificity is taken into account by using the number and test outcomes of control and case
sera used for test validation in the estimation of the cumulative incidence [12–16]. (Basically,
sensitivity and specificity, as well as their uncertainty, are estimated as the Binomial probabili-
ties of detecting true positives and negatives, respectively.) Similar to the Rogan-Gladen esti-
mator, this framework dichotomizes the data using a predefined cutoff by assigning a positive
or negative test result for each individual in the cohort. Thus the Bayesian framework is also
cutoff-based.
In this study, we use an alternative approach to estimate cumulative incidence that does not
rely on a predefined cutoff. This approach has been developed to study the cumulative inci-
dence of infections with various pathogens and is referred to as mixture model [17–23].
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Throughout this study, we will also refer to this method as mixture model method. Rather than
relying on dichotomized serological test data and correcting for the test’s sensitivity and speci-
ficity, this method uses the quantitative test measures together with data on the distribution of
these measures in controls and confirmed cases. Serological tests differ in the quantitative test
measures they yield. Some measure optical densities, other neutralization titers (NT50). The
mixture-model approach can be applied to all these measures irrespective of the type of assay
that is used, as long as the measures of the serosurvey and test validation data have the same
units. If there is significant variation in measures between laboratories, as suggested by Benda-
vid et al. [11], measurements should be standardized or performed in the same laboratory.
Using simulated serosurveys, we investigated the statistical properties of mixture-model
estimators of cumulative incidence, and compare them to cutoff-based estimators. Further, we
conducted power analyses to determine the required size of a serosurvey for serological tests
with varying accuracies. We also studied how the statistical power of the mixture model esti-
mator is affected by the number of control and case sera used for the validation of the serologi-
cal assay. This sheds light on the under-explored relationship between the effort put into test
validation on the one hand, and the serosurvey on the other.
Last, we addressed an issue that can only be studied with the mixture model approach: the
detection of a discrepancy between the serological observations in the epidemiological surveys
and the quantitative test measures collected during the validation phase of the serological
assay. There is evidence that individuals who underwent an asymptomatic or mild infection
have lower antibody levels than those who had a severe infection [4, 24, 25]. A past asymptom-
atic or mild infection is therefore detected with a lower sensitivity than a severe infection for
most serological assays [4, 24]. This results in a biased estimate of the cumulative incidence
with the cutoff-based methods if the serological assay is not validated with a representative
sample of cases. The mixture model approach, however, can detect such a discrepancy, correct
for it, and even estimate the relative incidence of the category of samples that was excluded
from the validation data. Thus, the mixture-model approach has the potential to map the
diversity of disease profiles, and could shed light on the yet-to-be-determined frequency of
asymptomatic infections with SARS-CoV-2.
Results
Mixture-model estimator outperforms cutoff-based methods
To compare the mixture model to the cutoff-based methods, we simulated serosurveys con-
ducted with serological tests of varying accuracies. As a proxy for the accuracy, we selected the
area under the ROC-curve (AUC-ROC) and varied it from 0.8 to 1. This range is consistent
with the AUC-ROC values of most currently available SARS-CoV-2 antibody tests [4, 7, 26].
(The sensitivity and specificity corresponding to the standard cutoffs across the range of
AUC-ROC values that we consider here, are given in S1 Fig) An overview of the cutoff-based
methods can be found in Table 1.
In the simulated serosurveys, we assumed cumulative incidences of 1%, 4% and 8% and
enrolled 10, 000 virtual individuals and used 5, 000 control and case sera for test validation.
We then derived estimates of the cumulative incidence with the cutoff-based methods and the
mixture-model approach, and repeated this 50 times for each test accuracy. We calculated 95%
confidence intervals for the uncorrected and Rogan-Gladen corrected cutoff-based methods
and the mixture model using a bootstrap procedure. A function for calculating these intervals
is provided in the R-package. The uncertainty in the estimates from the Bayesian framework
are determined based on the 95% credible interval.
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S2 Fig illustrates the well-known fact that the observed fraction of positive serological tests
is a biased estimator of the cumulative incidence. For both cutoffs we consider, the maximum
Youden and the high specificity cutoffs, the bias is substantial, increases for test of lower accu-
racy, and, depending on the cutoff, can lead to over- of underestimation of the cumulative
incidence.
The results of the analyses that take the sensitivity and specificity of the serological test into
account are shown in Fig 1. We find that the Rogan-Gladen correction [8] (see Methods)
results in unbiased estimations of the cumulative incidence (see Fig 1A). Note that for low
cumulative incidence levels or low test accuracy, the corrected point estimate of the prevalence
can become negative. This is due to the fact that the number of observed seropositives—being
a realization of a stochastic process—can be smaller than the expected number of false posi-
tives. For the same reason, the Rogan-Gladen correction gives rise to more variable estimates
compared to the mixture model for low cumulative incidence levels and low test accuracies
(see Fig 1B). In contrast, the mixture-model estimator does not inflate the variation of point-
estimates and does not result in negative estimates for any true cumulative incidence level or
test accuracy.
The Bayesian framework results in slightly overestimated cumulative incidences for low
incidence levels and low test accuracy. This is likely due to the flat priors that have been used.
Fig 1B shows that the 95% credible intervals obtained by the Bayesian framework are larger
than the 95% confidence intervals of the mixture-model estimator. Thus, the mixture model
also outperforms the Bayesian framework.
Mixture model leads to more reliable estimates of the temporal trends in
cumulative incidence
In the ongoing SARS-CoV-2 pandemic, the cumulative incidence is still increasing, and an
estimation of its temporal trend is an urgent public health objective. To assess how well the dif-
ferent methods can estimate temporal trends in cumulative incidence, we simulated serosur-
veys during an ongoing epidemic. In particular, we assumed that the cumulative incidence
increases from 1.5% to 15%.
We found that the uncorrected cutoff-based methods both underestimate the temporal
trend in the cumulative incidence (Fig 2). The Rogan-Gladen estimator removes the bias in
the estimate, but introduces a large variation in the point-estimates of the temporal trend. This
is similar for the cutoff-based methods within the Bayesian framework. The estimate for the
Table 1. Overview of methods for the estimation of cumulative incidence.
Name in this study Cutoff-
based











Post-hoc Rogan-Gladen correction Cumulative incidence [8]
yes Max Youden Post-hoc Rogan-Gladen correction Cumulative incidence




Simultaneous, Bayesian estimation of cumulative





yes Max Youden Simultaneous, Bayesian estimation of cumulative
incidence, sensitivity and specificity
Cumulative incidence, sensitivity
and specificity
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Fig 1. Point-estimates of cumulative incidence using the cutoff-based methods and the mixture model. Each violin represents 50 in silico
serosurveys conducted with cohorts of 10, 000 virtual individuals and the points represent the median values. (A) Point-estimates of the cumulative
incidence. The dashed line indicates the true cumulative incidence we assumed in the simulations. Please note that the scale of the y-axis differs between
the sub-figures. (B) Size of the 95% uncertainty intervals. For the Rogan-Gladen and mixture-model estimates, the uncertainty intervals are the 95%
confidence intervals, which we calculated with the bootstrap method (see Methods). For the Bayesian estimators, the uncertainty interval are the 95%
credible intervals.
https://doi.org/10.1371/journal.pcbi.1008728.g001
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temporal trend can even be negative for the reason mentioned above. In contrast, the mixture
model leads to more reliable point-estimates of the temporal trend without inflating their
variation.
Low specificity/sensitivity can be compensated by enrolling more
participants into the serosurvey
To understand how the test accuracy and the number of individuals enrolled in the serosurvey
affect the statistical power of serosurveys analyzed with the mixture-model approach, we simu-
lated serosurveys with tests characterized by varying AUC-ROC values and different numbers
of individuals enrolled, and evaluated their success. A serosurvey was defined to be successful
Fig 2. Estimated fold increases in cumulative incidence for the cutoff-based methods and the mixture model. In
the simulated serosurveys, we assumed the cumulative incidence to increase from 1.5% to 15%, resulting in a true fold
increase of 10 (dashed line). The violins show the distribution of 50 in silico serosurveys for both cumulative incidence
levels conducted with cohorts of 10, 000 individuals and a test with an AUC-ROC value of 0.975. The dots indicate the
median value.
https://doi.org/10.1371/journal.pcbi.1008728.g002
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if the estimate of the cumulative incidence was sufficiently close to the true cumulative inci-
dence (see Methods). The statistical power is defined as the fraction of successful in silico
serosurveys.
We find that a lower accuracy of the serological test can be compensated by higher sample
sizes (Fig 3A), but only if the accuracy is not too low. For example, to achieve a statistical
power of 0.9, 1, 000 individuals need to be enrolled into the serosurvey for a high-accuracy
test (AUC-ROC = 0.975). In contrast, for a lower accuracy test (AUC-ROC = 0.9) 3, 000 are
required (Fig 3B). However, for a test accuracy lower than 0.9 enrolling even up to 10, 000
individuals does not increase the power of the test above 0.9.
The number of control and case sera used for validation of serological tests
impacts the reliability of the cumulative incidence estimate
The mixture-model estimator relies directly on the quantitative test measures and their distri-
bution for control and case sera. Therefore, the reliability of the method is expected to depend
on the precision with which these distributions have been determined, which depends on the
number of control and case sera used in test validation. Here, we asses how the number of
control and case sera influences the variation of the estimated cumulative incidences and the
power of the serosurvey (see Methods).
In our simulations, the confidence interval of the estimated cumulative incidence decreases
with the number of control and case sera used for the validation of the test (Fig 4C). As a result,
the statistical power increases for higher numbers of control and case sera (Fig 4D). Addition-
ally, we find that, with increasing test accuracy, the number of control and case sera required
Fig 3. Statistical power of the mixture model. In all simulations, the number of control and case data is fixed to
5, 000 each and the true cumulative incidence level is 8%. (A) Statistical power versus the number of individuals in the
serosurvey for varying levels of test accuracy (AUC-ROC). The power is calculated as the fraction of simulated
serosurveys that resulted in a cumulative incidence estimate that is within 25% of the true cumulative incidence and for
which the true cumulative incidence level lies within 2 standard deviations of the estimated value. Each point in the
graph represents the result of 3, 000 in silico serosurveys. (B) The minimal number of virtual individuals necessary to
obtain a statistical power of 0.9 over a range of AUC-ROC values.
https://doi.org/10.1371/journal.pcbi.1008728.g003
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to obtain a statistical power of 0.9 decreases. For a true prevalence of 8% and 10, 000 individu-
als in the serosurvey, as used in Fig 4D, and a AUC-ROC value of 0.9, 2, 500 control and case
sera samples are needed to obtain a statistical power of 0.9 (Fig 4D). However, for a AUC-ROC
value of 0.975, sampling 750 cases and controls would be sufficient.
A low number of control and case sera for the validation of the test can be compensated by
a higher number of individuals in the serosurvey (Fig 4E). The relation between the number of
control and case sera and the minimal number of individuals in the serosurvey depends on the
accuracy of the serological assay.
Detecting discrepancies between test validation and serosurvey data
The reliance of the mixture model on quantitative test data, allows us to investigate inconsisten-
cies between the populations used for validating the test on the one hand, and the population
recruited into the serosurvey on the other. For example, assume that the serological test has
been validated only with sera from individuals who underwent a severe infection, in addition to
sera from controls (see Fig 5A). If these severe cases used in the validation set are a good repre-
sentation of the infections in the population, we would expect our serosurvey data to look like
Fig 5C. However, if other types of infections are very prevalent, such as mild or asymptomatic
infections, that are characterized by distributions of antibody levels very different from severe
infections (see Fig 5B), the resulting serosurvey data would look like those shown in Fig 5D. We
have extended the mixture model such that it can detect from the serosurvey data whether there
exists an additional distribution of cases that was not included in the validation data.
We set up a simulation assuming three distributions of test measures. These distributions
can be thought of as corresponding to severe and asymptomatic cases and controls, but could
also describe classes of infections that differ by a factor other than disease severity. We further
assume that the total cumulative incidence in the population is 8%, of which 20% were asymp-
tomatic infections, consistent with the current estimate [27]. We then simulate a serosurvey
with 10, 000 individuals that results in quantitative test measures randomly drawn from these
three distribution according to their cumulative incidences.
First, we show that ignoring a missing class of case sera leads to an underestimation bias in
the estimated cumulative incidence by analysing the simulated serosurvey data assuming a
mixture model based on quantitative test measure of only severe cases and controls (see Fig
6A). This misspecified mixture model, however, is valuable as a null model against which a
more complex likelihood can be tested. Fig 6A compares the misspecifation scenario to the
scenario where both asymptomatic and severe infections have been included into the distribu-
tion of the case sera of the validation data.
Secondly, we fit the three-distribution likelihood to estimate the cumulative incidences of
asymptomatic and severe cases, and the mean of the test measure distribution of asymptomatic
cases. This analysis—without knowledge of the third distribution—succeeds in estimating the
total cumulative incidence without bias (Fig 6B). It also yields estimates for the cumulative
incidences for asymptomatic and severe cases separately (Fig 6B). The identifiability of the
individual cumulative incidences depends strongly on how distinct the test measure distribu-
tions of asymptomatic and severe cases and the controls are. In practice, one can test for the
existence of a missing case distribution by applying a likelihood ratio test on the extended
model and the standard mixture model.
Discussion
In this study, we evaluate the performance of a mixture-model approach in estimating the
cumulative incidence of a population. Throughout this paper, we refrained from referring to
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Fig 4. Effect of varying the number of control and case sera used to calibrate the serological test. (A) An example of the true
distribution (solid lines) of the control (grey) and case (orange) sera, the data simulated from those distributions (histograms) and
the inferred densities (dashed lines) used in the inference of the cumulative incidence. Here, 150 control and case sera have been
simulated and the AUC-ROC value of the test is equal to 0.975. (B) Point estimates of cumulative incidence for various numbers of
control and case sera used to calibrate the serological test and three AUC-ROC values. Each violin shows the distribution of the
estimated cumulative incidence of 50 in silico serosurveys conducted with cohorts of 10, 000 virtual individuals. The red line shows
PLOS COMPUTATIONAL BIOLOGY Cutoff-free approaches for the estimation of the cumulative incidence of SARS-CoV-2
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sero-prevalence for two reasons. First, sero-prevalence is the frequency of sero-positive indi-
viduals in a population and hence inherently coupled to cutoffs. Focusing on the distribution
of antibody levels without dichotomizing into sero-positives and -negatives makes it more
challenging to determine sero-prevalence. Second, serological tests are usually validated
against pre-pandemic sera and sera from individuals with confirmed infection, and not against
sera that do or do not contain pathogen-specific antibodies. As a consequence of this choice
of positive and negative controls, false positives are individuals that have specific antibodies
despite not having been infected, and not individuals for which the test wrongly shows they
harbor specific antibodies while they actually do not. Correcting for false positives and nega-
tives by both cutoff-based and mixture model methods therefore results in an estimate of
cumulative incidence rather than of sero-prevalence. This distinction between sero-prevalence
and cumulative incidence is common in epidemiological studies (see for example a metastudy
on the cumulative incidence of the 2009 influenza pandemic by Van Kerkhove et al [28]).
The mixture-model approach uses the quantitative serological test measurements before
they have been dichotomized, i.e. categorized as “positive” or “negative” with a cutoff. We con-
firm that cutoff-based estimators that do not correct for the sensitivity and specificity of the
serological test can lead to strong biases in the estimate of cumulative incidence and its time
trends, especially for situations of low cumulative incidence [8]. Even though the commonly
the true cumulative incidence we assumed in the simulated serosurveys (8%). (C) Size of the 95% confidence intervals of the
estimated cumulative incidences. (D) Statistical power versus the number of control and case sera used in the validation data for
varying levels of test accuracy (AUC-ROC). Each point in the graph represents the result of 3, 000 in silico serosurveys. (E) The
minimal number of virtual individuals necessary to obtain a statistical power of 0.9 over a range of number of control and case sera
in the validation data.
https://doi.org/10.1371/journal.pcbi.1008728.g004
Fig 5. Conceptual figure on how a discrepancy between the test validation and serosurvey data can be detected. (A) Histograms
of simulated validation data from controls and severe cases. (B) Histograms of simulated validation data from controls and severe
and asymptomatic cases. (C) Histogram of simulated serosurvey data when all infections in a population are severe. (D) Histogram
of simulated serosurvey data when one third of all cases is asymptomatic and two thirds severe.
https://doi.org/10.1371/journal.pcbi.1008728.g005
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Fig 6. Estimates of the cumulative incidence in a population where individuals have been uninfected, as well as
symptomatically and severely infected. The x-axes represent the AUC-ROC value between the asymptomatic and
severe case distribution. The AUC-ROC value between the control and the severe case distributions is 1. Each violin
represents the result of 50 simulated serosurveys with 10, 000 individuals per serosurvey. The true total cumulative
incidence of severe and asymptomatic infections is 10%, of which 20% are asymptomatic. (A) Cyan violins show
PLOS COMPUTATIONAL BIOLOGY Cutoff-free approaches for the estimation of the cumulative incidence of SARS-CoV-2
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used Rogan-Gladen correction and the Bayesian framework that accommodates the sensitivity
and specificity alleviate the biases, the estimates of the cumulative incidence have generally
wider confidence or high probability intervals than the mixture-model estimates. This is espe-
cially pronounced for low levels of cumulative incidence and low test accuracies, and should
therefore be of value specifically for SARS-CoV-2 serosurveys early in the pandemic.
Paired with the simulation of serosurveys, the mixture model can provide guidance on the
design of serosurveys. It reveals how the test’s accuracy, the number of individuals in the sero-
survey, and the number of control and case sera affect in the statistical power of the serosurvey.
First, we found that a low test accuracy can, up to a level, be compensated by higher sample
sizes in the serosurvey. Specifically, a compensation is possible for AUC-ROC values higher
than 0.9, but even for these relatively accurate tests the increase in required sample size can be
large. Thus, serosurveys need to employ tests of sufficiently high accuracy to be feasible, and
increasing a tests accuracy pays off in terms of smaller serosurveys. Secondly, we showed how
the number of control and case sera used in the validation of the test influence the statistical
power of a serosurvey. Please note that the increasing the number of case and control sera in
test validation do not make the test more accurate, but provide more exact estimates of the
test’s accuracy. For example, to obtain a statistical power of 0.9 for a serosurvey performed at a
true cumulative incidence level of 8% and a test accuracy of AUC-ROC = 0.975, 3, 000 individ-
uals need to be enrolled if the test has been validated on 750 control and case serum samples. If
the number of control and case sera used for test validation is equal to 2, 500 each, only 1, 000
individuals would have to be enrolled in the serosurvey for the same statistical power. It is
therefore worthwhile to carefully weigh the benefits of more thorough test validation against
that of expanding the serosurvey. The fact that the number of serum samples used to deter-
mine the accuracy of a serological test affects the feasibility and statistical power of serosurveys
is an argument for a collaborative scientific effort to establish large, standardized, open valida-
tion data sets for SARS-CoV-2 serological tests.
The mixture-model approach as well as the cutoff-based methods rely on representative
data from cases. Representative means this cohort should contain individuals who have under-
gone severe, mild and asymptomatic infections, and the proportions of the infections with dif-
ferent severities should recapitulate the proportions in the population. We have illustrated that
an over-representation of severe cases compared to asymptomatic cases in the validation of the
serological test leads to underestimation of the cumulative incidence. Thus, it is preferable to
include cases detected by contact tracing rather than by more biased detection channels, such
as hospitalisation.
Unlike the cutoff-based methods, however, the mixture-model approach allows us to infer
the presence of cases that were not used for the validation of the test. To this end, the likelihood
of the mixture model is extended by an unknown distribution of test measures. In addition to
being able to identify a discrepancy of test validation versus serosurvey data, this extended like-
lihood also allows for the estimation of the cumulative incidence of the subpopulation with the
unknown distribution (Fig 6B). This is crucial for a reliable estimation of the true extent of the
current SARS-CoV-2 pandemic. The mixture model can be easily extended to include more
than two types of cases. We recommend to always use a mixture model with an additional
unknown distribution and to test its fit with a likelihood-ratio test against a null model that
estimates of the total cumulative incidence based on an inferred case distribution containing only severe case sera,
whereas purple violins show estimates where the case distribution is containing both asymptomatic and severe case sera.
(B) The estimated cumulative incidence of the mild (light purple) and the severe (dark purple) cases, where the case sera
distribution is only based on severe cases, but the likelihood equation also estimates the shape of the asympotomatic
cases and their relative prevalence.
https://doi.org/10.1371/journal.pcbi.1008728.g006
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includes all known case distributions. This guards against strong biases arising from neglecting
a large fraction with distinct test measure distributions. However, the biological interpretation
of an additional distribution is complex. In addition to the severity of infection, many alterna-
tive factors could influence the antibody response levels. Most notably, antibody levels have
been found to drop over time [29] which can introduce heterogeneities in test measure distri-
butions over time.
The mixture-model approach is applicable over a broad range of serological tests and
accepts any common type of quantitative test measures of specific antibody levels, such as opti-
cal densities or “arbitrary units” in ELISAs or neutralization titers that inhibit viral replication
to any degree specified (e.g NT50 or NT90) in neutralization assays. It is not essential that
these measures are linearly correlated with the level of antibodies. It is important, however,
that the isotype, units and scales are the same as those for the test measure distributions of con-
trol and case sera. While the mixture-model approach has been developed to increase the reli-
ability of cumulative incidence estimates especially for tests with low accuracy, it of course also
works for perfect tests.
Similar to the cutoff-based methods, it has been shown that the mixture model can be easily
extended by categorical or continuous covariates of the cumulative incidence, such as sex or
age [17–23]. Also temporal changes in cumulative incidence—as predicted, for example, by
epidemiological models—can be incorporated into this framework. The mixture model pro-
vides a more natural approach to integrating multiple test measures, such as IgA and IgG lev-
els. In cutoff-based methods, in contrast, including multiple measures may require complex
cutoff functions that depend on these multiple measures and will complicate the determina-
tion of sensitivity and specificity.
This work as well as other similar studies that investigate the effect of test accuracy on
estimating cumulative incidence highlight the necessity of integrating the development of
serological tests with the design of the serosurveys, in which they will be applied [30]. This is
especially relevant during the current SARS-CoV-2 pandemic as the serological tests are devel-
oped at the same time as the serosurveys are being conducted.
Methods
The likelihood of the mixture model
The mixture model approach to inference relies directly on the quantitative measures obtained
from serological tests [18–21]. It estimates the cumulative incidence (π) by maximizing the
likelihood of observing the quantitative test measures in the serosurvey data, given the distri-







pðsi ¼ 1jpÞ pðUijsi ¼ 1Þ þ pðsi ¼ 0jpÞ pðUijsi ¼ 0Þ
�
ð1Þ
Here, U is a vector with the quantitative test measures of all n tests, σ is a binary vector of
length n with their underlying true serological status (1 for infected and 0 for not infected).
The probabilities p(Ui|σi = 1) and p(Ui|σi = 0) capture the distributions of quantitative test
measures of control and case sera, and p(σi = 1|π) and p(σi = 0|π) denote the probability of
sampling individuals who have been truly infected or not. The distributions of the quantita-
tive test measures of control and case sera are derived from the observations of known cases
and controls. The units of U can be anything that is commonly used in serological tests, such
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Fig 7. Conceptual diagram of the distribution of the quantitative test measures for control and case sera. (A) Hypothetical probability density of
quantitative test measures of control sera and three possible case sera distributions. (B) ROC-curves corresponding to the distribution of quantitative
test measures of the control sera and each of the possible distributions for the case sera. (C) Visualization of the ‘maximal Youden’ and ‘high specificity’
cutoffs. (D) Visualization of the ‘maximal Youden’ and ‘high specificity’ cutoffs in the ROC curves.
https://doi.org/10.1371/journal.pcbi.1008728.g007
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as optical densities obtained from ELISAs or neutralization titers obtained in neutralization
assays.
Cutoff-based methods
For the cutoff-based methods, the quantitative test measures are dichotomized into seroposi-
tives and negatives using a cutoff. There are many ways to estimate a cutoff value for a test [31,
32]. One strategy is to set the cutoff such that the test is highly specific (99%) (see Fig 7C). This
is equivalent to minimizing the number of false positives. This will go at the cost of the sensi-
tivity and will lead to more false negatives. This method is referred to as the ‘high specificity’
method throughout this study.
Another method that is often used to determine the cutoff is to maximize the Youden index
(Youden index = sensitivity + specificity − 1 [33]) (see Fig 7C). Graphically, this is equivalent
to maximizing the distance between the diagonal and the receiver-operator characteristic
(ROC) curve (see Fig 7D). This method is referred to as the ‘max Youden’ method throughout
this study.
To estimate the cumulative incidence in the data with a cut-off based method, the binomial
cumulative incidence estimate q is corrected for the sensitivity and specificity of the test. The
standard correction is described by Rogan and Gladen [8]:
p ¼
qþ s   1
r þ s   1
: ð2Þ
Here, r is the sensitivity and s the specificity of the test, and π is the corrected estimator of
cumulative incidence. Effectively, this correction adds the expected number of false negative
and subtracts the expected number of false positives from the number of observed positives.
The correction works best when the expected number of false positives is smaller than the
observed number of positives. We apply this correction to the maximal Youden and the high
specificity method and refer to it as the ad-hoc correction.
An alternative way to account for the sensitivity and specificity of the serological test is by
using a Bayesian approach which simultaneously estimates the cumulative incidence and the
sensitivity and specificity of the serological test [12–14, 16, 30]. This is done based on the sero-
survey data and the test validation data. Eq 3 provides the joint posterior distribution of these
three parameters, as given in Larremore et al. [30]. Here, X represents the serosurvey data, V
the validation data, n+ the number of positive tests in the serosurvey data, Nfields the number of
individuals in the serosurvey, Nneg the number of control sera, Npos the number of case sera, tp
the number of true positives in the cases sera and tn the number of true negatives in the con-
trol sera. We apply this method using the cut-offs calculated with the maximal Youden and the
high specificity method.
Prðp; s; rjX;VÞ /
�
ð1   sþ pðr þ s   1ÞÞn
þ




stnð1   sÞNneg   tnrtpð1   rÞNpos  tp:
ð3Þ
Simulations
We simulate serosurveys by assuming given cumulative incidences and distributions of the
quantitative test measures for control and case sera. For each virtual individual enrolled in
these in silico serosurveys, we conduct a Bernoulli trial with the probability of success set to
the chosen cumulative incidence. In a second step, we simulate the serological test of each
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individual. To this end, we draw a random quantitative test measure from the distribution of
either case or control sera—depending on whether the individual is truly seropositive or not.
Besides the serosurvey, we also simulate data of known control and case sera. Unless oth-
erwise specified we simulated 5, 000 control as well as case sera. For each of these 5, 000 con-
trol and case sera we randomly drew a value from the assumed distribution. We assume the
distribution of quantitative test measures for the control sera to be Γ-distributed with a
shape and scale parameter of 1, which results in a mean of 1, and the distribution for case
sera to be Γ-distributed with varying shape parameters and a scale parameter of 1. The scale
parameter of the distribution for case sera determines the amount of overlap between the
quantitative test measure of cases with controls, and thus modifies test accuracy as measured
by AUC-ROC (Fig 7).
The simulated validation data are used to perform the estimation of the cumulative inci-
dence with the methods described above. For the mixture model, we fitted a density distribu-
tion through the control and case sera data with the function ‘density’ in R [34]. For the
Rogen-Gladen correction, we use the simulated control and case sera to calculate the sensitiv-
ity and specificity of the test. For the Bayesian method, we use the simulated control and case
sera to include also the uncertainty in the sensitivity and specificity of the test in the cumulative
incidence estimate.
Confidence interval
We suggest a two-step bootstrap procedure to calculate a confidence interval for the estimated
cumulative incidence inferred with the mixture model and the ad-hoc corrected cutoff-based
methods. First, we re-sample the test measures of control and case sera, and use the re-sampled
dataset to obtain a new fitted density distribution for both the control and case sera. Second,
we re-sample the test measures of the serosurvey, and, using the new density distributions of
the test measures for the control and case sera, obtain bootstrap estimates of the cumulative
incidence. This procedure makes sure that the uncertainties arising from the lack of test
accuracy as well as the lack of precision in the test measure distributions are appropriately
accounted for in the estimation of the cumulative incidence. An R-function that performs this
procedure is included in the supplementary R-package.
In the results, we compare the mixture model to a Bayesian implementation of the cutoff
based methods that includes uncertainty in the sensitivity and specificity [15, 16]. These meth-
ods provide credible intervals instead of confidence intervals.
Power analysis
To estimate the statistical power of a serosurvey, we conducted 3, 000 serosurveys for each
given test accuracy and sample size. The power is determined as the proportion of simulations
for which the cumulative incidence is estimated successfully. We define an estimate to be suc-
cessful when it deviates less than 25% from the true cumulative incidence and the true cumula-
tive incidence is within 2 standard deviations of the estimate.
Incorporating distinct distributions for asymptomatic and severe case sera
Eq 4 represents a likelihood that allows for the possibility that there are various types of case
sera with distinguishable distributions (See Fig 5B) [23]. For the sake of simplicity, we assume
that there are two types of case sera: those from individuals who underwent a severe infection
(severe cases) and those from individuals who underwent an asymptomatic infection
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Compared to Eq 1, σi is now a categorical value that represents whether an individuals is sero-
negative (0), seropositive due to an asymptomatic infection (1) or seropositive due to a severe
infection (2). πA is the cumulative incidence of asymptomatic infections and πS the cumulative
incidence of severe infections. This likelihood is formally equivalent to the one presented in van
Boven et al [23], without the age-structure. We used the extended likelihood to estimate the total
cumulative incidence, the cumulative incidence of asymptomatic cases and the shape parameter
of the distribution of quantitative test measures of the asymptomatic case sera.
The identifiability and confidence of the estimates of these three parameters depends on the
amount of overlap between the distribution of the asymptomatic and severe case sera and the
overlap between those and the control sera. In our simulations, we hold the area under the
ROC-curve between the control and severe case sera constant, at a level of 1, while we vary the
area under the ROC curve between the asymptomatic and severe case sera. We set the mean of
the distribution of asymptomatic cases always to a lower value than that of the severe cases (see
Fig 5B). Both these means are larger than 1, which is the mean of the distribution of test mea-
sures for control sera. We use a scale parameter of 1 for both distributions.
Implementation
The likelihood function for estimating cumulative incidence as well as the simulations were
implemented in the R language for statistical computing [34]. The Bayesian correction is
implemented with the ‘Rstan’ package in R [35, 36]. An R-package containing the code can be
found here: https://gitlab.ethz.ch/jbouman/pist.
Supporting information
S1 Fig. Sensitivity and specificity corresponding to the cutoff-based methods across the
range of AUC-ROC values we consider in this study.
(TIF)
S2 Fig. Performance of the uncorrected cutoff-based methods. (A) Estimated cumulative
incidence for three levels of true cumulative incidence. (B) Half of the 95% confidence inter-
vals estimated based on the bootstrap method for both uncorrected cutoff-based methods.
(TIF)
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